Amalgamated Bank’s AN2 Therapeutics ANTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,767
Closed -$17K 3035
2023
Q1
$17K Sell
1,767
-85
-5% -$945 ﹤0.01% 2688
2022
Q4
$18K Buy
1,852
+452
+32% +$6.05K ﹤0.01% 2772
2022
Q3
$24K Buy
1,400
+6
+0.4% +$70 ﹤0.01% 2755
2022
Q2
$11K Buy
+1,394
New +$18.5K ﹤0.01% 2974

Other funds holding ANTX

Amalgamated Bank's ANTX Position: Q2 2023 in Review

Amalgamated Bank sold out of AN2 Therapeutics (ANTX) in Q2 2023, closing a stake of 1,767 shares — an estimated $17K sold.

Amalgamated Bank first reported a position in ANTX in Q2 2022 and held it in 4 quarters. The position peaked at $24K in Q3 2022. 31 funds tracked by Wall St. Rank hold ANTX as of Q2 2023.

  • Amalgamated Bank reported no remaining AN2 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Amalgamated Bank sold 1,767 AN2 Therapeutics shares in Q2 2023, an estimated $17K.
  • Amalgamated Bank first reported a position in AN2 Therapeutics in Q2 2022 and held it in 4 quarters.
  • Amalgamated Bank's AN2 Therapeutics position peaked at $24K in Q3 2022.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2023.

Based on Amalgamated Bank's 13F filing for Q2 2023, filed 11 Aug 2023.